UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 590

Sortiert nach

Safety profile of belimumab: pooled data from placebo-controlled phase 2 and 3 studies in patients with systemic lupus erythematosus

Lupus, 2013-02, Vol.22 (2), p.144-154

2013

Volltextzugriff (PDF)

Celecoxib Versus Naproxen and Diclofenac in Osteoarthritis Patients: SUCCESS-I Study

The American journal of medicine, 2006-03, Vol.119 (3), p.255-266

2006

Volltextzugriff (PDF)

Hydroxychloroquine (HCQ) in lupus pregnancy: double-blind and placebo-controlled study

Lupus, 2001-06, Vol.10 (6), p.401-404

2001

Volltextzugriff (PDF)

PO.5.102 Pharmacokinetic modelling of belimumab in patients with lupus nephritis: intravenous and subcutaneous loading dose regimen justification

Lupus science & medicine, 2022-10, Vol.9 (Suppl 2), p.A80-A81

2022

Volltextzugriff (PDF)

Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial

The Lancet (British edition), 2011, Vol.377 (9767), p.721-731

2011

Volltextzugriff (PDF)

PO.5.105 The effect of belimumab on extra-renal outcomes: results from the phase 3, randomised, placebo-controlled, 104-week bliss-ln study in patients with active lupus nephritis

Lupus science & medicine, 2022-10, Vol.9 (Suppl 2), p.A83-A84

2022

Volltextzugriff (PDF)

PO.5.101 The effect of belimumab on renal outcomes in a pre-specified subgroup analysis of a phase 3 randomised trial in a european population with lupus nephritis

Lupus science & medicine, 2022-10, Vol.9 (Suppl 2), p.A79-A80

2022

Volltextzugriff (PDF)

14th International Congress on Antiphospholipid Antibodies Task Force Report on Antiphospholipid Syndrome Treatment Trends

Autoimmunity reviews, 2014-06, Vol.13 (6), p.685-696

2014

Volltextzugriff (PDF)

Baseline Predictors of Systemic Lupus Erythematosus Flares: Data From the Combined Placebo Groups in the Phase III Belimumab Trials

Arthritis & rheumatology (Hoboken, N.J.), 2013-08, Vol.65 (8), p.2143-2153

2013

Volltextzugriff (PDF)

Improvements in health-related quality of life with belimumab, a B-lymphocyte stimulator-specific inhibitor, in patients with autoantibody-positive systemic lupus erythematosus from the randomised controlled BLISS trials

Annals of the rheumatic diseases, 2014-05, Vol.73 (5), p.838-844

2014

Volltextzugriff (PDF)

Efficacy of belimumab on renal outcomes in patients with systemic lupus erythematosus: A systematic review

Autoimmunity reviews, 2017-03, Vol.16 (3), p.287-293

2017

Volltextzugriff (PDF)

Factors associated with first thrombosis in patients presenting with obstetric antiphospholipid syndrome (APS) in the APS Alliance for Clinical Trials and International Networking Clinical Database and Repository: a retrospective study

BJOG : an international journal of obstetrics and gynaecology, 2019-04, Vol.126 (5), p.656-661

2019

Volltextzugriff (PDF)

Drug delivery systems improve pharmaceutical profile and facilitate medication adherence

Advances in therapy, 2005-11, Vol.22 (6), p.559-577

2005

Volltextzugriff (PDF)

Immunology of pregnancy and reproductive health in autoimmune rheumatic diseases. Update from the 11th International Conference on Reproduction, Pregnancy and Rheumatic Diseases

Autoimmunity reviews, 2023-03, Vol.22 (3), p.103259, Article 103259

2023

Volltextzugriff (PDF)

Patient–health care provider relationship: how can it impact on APS (Hughes’ syndrome) adherence to treatment?

Lupus, 2014-10, Vol.23 (12), p.1265-1268

2014

Volltextzugriff (PDF)

Immunotherapy Efficacy in Advanced Hepatocellular Carcinoma in a Diverse and Underserved Population in the United States

Journal of hepatocellular carcinoma, 2024-01, Vol.11, p.257-269

2024

Volltextzugriff (PDF)

Electrostatic flexible film based smart window: Optical design, performance and residual charge investigation

Solar energy, 2014-12, Vol.110, p.667-672

2014

Volltextzugriff (PDF)

The use of angiogenic and antiangiogenic factors in the differential diagnosis of pre-eclampsia, antiphospholipid syndrome nephropathy and lupus nephritis

Lupus, 2014-10, Vol.23 (12), p.1299-1301

2014

Volltextzugriff (PDF)

Racial and ethnic differences in response to medicines: Towards individualized pharmaceutical treatment

Journal of the National Medical Association, 2002-10, Vol.94 (10), p.1-26

2002

Volltextzugriff (PDF)

Catastrophic antiphospholipid syndrome. Clinical and laboratory features of 50 patients

Medicine (Baltimore), 1998-05, Vol.77 (3), p.195-207

1998

Volltextzugriff (PDF)

Using the GRADE system in diagnostic strategy: the case of antiphospholipid syndrome

Lupus, 2014-10, Vol.23 (12), p.1292-1294

2014

Volltextzugriff (PDF)

Relevance of different results of different anti-double-stranded DNA assays in reporting clinical studies: comment on the article by Petri et al. Reply

Arthritis & rheumatology (Hoboken, N.J.), 2014-02, Vol.66 (2), p.480-480

2014

Volltextzugriff (PDF)

SAT0197 Baseline laboratory characteristics from the combined placebo groups in the bliss trials are predictive of severe flare at 24 weeks

Annals of the rheumatic diseases, 2013-06, Vol.71 (Suppl 3), p.538-538

2013

Volltextzugriff (PDF)

SAT0204 Predictors for SLE flares: Baseline disease activity and demographic characteristics from the bliss trials’ combined placebo groups

Annals of the rheumatic diseases, 2013-06, Vol.71 (Suppl 3), p.540-541

2013

Volltextzugriff (PDF)

Obstetric antiphospholipid syndrome: still a challenge

Lupus, 2010-04, Vol.19 (4), p.457-459

2010

Volltextzugriff (PDF)

1 – 25 von 590

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(518)
Mit Volltextzugriff
(459)

Publikationsform

1 weiteren anzeigen...

Weniger anzeigen...

Sprache

Englisch
(590)
Japanisch
(73)
Russisch
(1)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Safety profile of belimumab: pooled data from placebo-controlled phase 2 and 3 studies in patients with systemic lupus erythematosus

Celecoxib Versus Naproxen and Diclofenac in Osteoarthritis Patients: SUCCESS-I Study

Hydroxychloroquine (HCQ) in lupus pregnancy: double-blind and placebo-controlled study

PO.5.102 Pharmacokinetic modelling of belimumab in patients with lupus nephritis: intravenous and subcutaneous loading dose regimen justification

Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial

PO.5.105 The effect of belimumab on extra-renal outcomes: results from the phase 3, randomised, placebo-controlled, 104-week bliss-ln study in patients with active lupus nephritis

PO.5.101 The effect of belimumab on renal outcomes in a pre-specified subgroup analysis of a phase 3 randomised trial in a european population with lupus nephritis

14th International Congress on Antiphospholipid Antibodies Task Force Report on Antiphospholipid Syndrome Treatment Trends

Baseline Predictors of Systemic Lupus Erythematosus Flares: Data From the Combined Placebo Groups in the Phase III Belimumab Trials

Improvements in health-related quality of life with belimumab, a B-lymphocyte stimulator-specific inhibitor, in patients with autoantibody-positive systemic lupus erythematosus from the randomised controlled BLISS trials

Efficacy of belimumab on renal outcomes in patients with systemic lupus erythematosus: A systematic review

Factors associated with first thrombosis in patients presenting with obstetric antiphospholipid syndrome (APS) in the APS Alliance for Clinical Trials and International Networking Clinical Database and Repository: a retrospective study

Drug delivery systems improve pharmaceutical profile and facilitate medication adherence

Immunology of pregnancy and reproductive health in autoimmune rheumatic diseases. Update from the 11th International Conference on Reproduction, Pregnancy and Rheumatic Diseases

Patient–health care provider relationship: how can it impact on APS (Hughes’ syndrome) adherence to treatment?

Immunotherapy Efficacy in Advanced Hepatocellular Carcinoma in a Diverse and Underserved Population in the United States

Electrostatic flexible film based smart window: Optical design, performance and residual charge investigation

The use of angiogenic and antiangiogenic factors in the differential diagnosis of pre-eclampsia, antiphospholipid syndrome nephropathy and lupus nephritis

Racial and ethnic differences in response to medicines: Towards individualized pharmaceutical treatment

Catastrophic antiphospholipid syndrome. Clinical and laboratory features of 50 patients

Using the GRADE system in diagnostic strategy: the case of antiphospholipid syndrome

Relevance of different results of different anti-double-stranded DNA assays in reporting clinical studies: comment on the article by Petri et al. Reply

SAT0197 Baseline laboratory characteristics from the combined placebo groups in the bliss trials are predictive of severe flare at 24 weeks

SAT0204 Predictors for SLE flares: Baseline disease activity and demographic characteristics from the bliss trials’ combined placebo groups

Obstetric antiphospholipid syndrome: still a challenge

Suchergebnisse filtern